Search

Displaying results 2331 - 2340 of 10000 in total
  1. Drug

    Azficel-T

    go.drugbank.com/drugs/DB11051
    ApprovedWithdrawn

    Expanded cells are then suspended in a cell medium. … Azficel-T is an autologous cellular product composed of fibroblasts indicated for improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults.

  2. Drug

    Ademetionine

    go.drugbank.com/drugs/DB00118
    ApprovedInvestigationalNutraceutical

    It possesses anti-inflammatory activity and has been used in treatment of chronic liver disease. (From Merck, 11th ed) … Physiologic methyl radical donor involved in enzymatic transmethylation reactions and present in all living organisms.

    Synonyms: SAM-eProducts: Heptral 500mg Gastroresistant Tablets
  3. Drug

    Lithium cation

    go.drugbank.com/drugs/DB01356
    ApprovedInvestigationalWithdrawn

    The active principle in these salts is the lithium ion Li+, which having a smaller diameter, can easily displace K+ and Na+ and even Ca+2, in spite of its greater charge, occupying their sites in several … They are used in the treatment of bipolar disorder, since unlike most other mood altering drugs, they counteract both mania and depression.

  4. Drug

    Zuranolone

    go.drugbank.com/drugs/DB15490
    ApprovedInvestigational

    binding to a non-benzodiazepine site on the receptor. … [A260776,A260786] Zuranolone was designed with a pharmacological profile of a neuroactive steroid in mind while also possessing a pharmacokinetics profile of an oral, once-daily dosing formulation.

  5. Drug

    Fencamfamin

    go.drugbank.com/drugs/DB01463
    ApprovedIllicitWithdrawn

    Fencamfamin (Glucoenergan, Reactivan) is a stimulant which was developed in the 1960s as an appetite suppressant. … It is especially useful in patients with chronic conditions due to its favourable safety profile.

  6. Drug

    Delgocitinib

    go.drugbank.com/drugs/DB16133
    ApprovedInvestigational

    After the first global approval in Japan,[A264693] delgocitinib was also approved by the European Commission on September 23, 2024. … [L51913] It works to reduce the inflammatory response in inflammatory skin disorders.[A264703] On July 23, 2025, delgocitinib was also granted approval by the FDA.[L53508]

  7. Drug

    Methacholine

    go.drugbank.com/drugs/DB06709
    Approved

    Asthma is a complex condition associated with phenomena such as airway hyperresponsiveness (AHR), in which the smooth muscle in the airways (ASM) excessively contracts in response to stimuli, reducing … [A229648, L31763] Methacholine was granted FDA approval on October 31, 1986, and is marketed under the trademark PROVOCHOLINE® by Methapharm Inc.[L31763]

  8. Drug

    Cidofovir

    go.drugbank.com/drugs/DB00369
    ApprovedInvestigational

    Cidofovir is an injectable antiviral medication employed in the treatment of cytomegalovirus (CMV) retinitis in patients diagnosed with AIDS. … [FDA label] It was manufactured by _Gilead_ and initially approved by the FDA in 1996, but has since been discontinued.[L6223]

  9. Drug

    Hydroxystilbamidine

    go.drugbank.com/drugs/DB14753
    Approved

    Hydroxystilbamidine isethionate is used in the therapy of some patients with nonprogressive blastomycosis of the skin, and pulmonary or systemic blastomycosis in children, with fewer side effects than … Hydroxystilbamidine isethionate is also used in pathology for diagnostic purposes.

  10. Drug

    Prucalopride

    go.drugbank.com/drugs/DB06480
    ApprovedInvestigational

    [A40254] Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009,[A40250] in Canada on December 7, 2011 and by the FDA on December 17, 2018.[L4880]